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Background
In recognition of the potential benefits of traditional medicine
to the world’s population, the World Health Organization
(WHO) established the Traditional Medicine Program under
the motto of ‘Health for All by the Year of 2000’ over three
decades ago (The Declaration of Alma-Ata resolved from the
International Conference on Primary Health Care by WHO–
UNICEF in Alma-Ata, USSR in 1978). Since then, WHO itself
has formulated numerous projects with traditional medicines,
and urged its Member States to initiate their own programs and
subsequent implementation on the national level of health care
programs and systems. To promote and facilitate such polices
in the Western Pacific Region of the WHO, where China, Japan,
Korea and Vietnam, Australia, New Zealand, Singapore and
many island countries scattered in the Pacific Ocean are located,
the Regional Office designated the WHO Collaboration Centers
for Traditional Medicine Research in China, Japan and Korea to
provide international cooperation among countries with interest
in Traditional Chinese Medicine (TCM). TCM does not neces-
sarily represent the traditional medicine of the People’s Republic
of China, rather the comprehensive traditional medicines of
China, Japan, Korea and Vietnam, and other countries whose
peoples have commonly shared in the historical development of
TCM and still include some traditional medical therapies in
their medical care system.
The Meeting Brought Together Many Nations
The meeting was held at the WHO Collaborating Center which
has been located in the Natural Products Research Institute,
Seoul National University, Seoul, Republic of Korea (hereafter
NPRI Center) since its designation in 1979. This institution
facilitated two major initiatives for providing global standard-
ization of TCM: (i) a proposal for establishment of the Forum
on Harmonization of Herbal Medicines; and (ii) a proposal for
development of the Treatment Guideline on Evidence-based
Traditional Medicine.
Following the agenda on the quality standard of herbal mate-
rials and preparations, an epoch on the milestone of moderniz-
ing TCM therapy, an initiative was introduced for establishing
guidelines of standard therapy practiced in TCM. There have
been two serious stumbling blocks; one is a lack of standard
diagnostic methodology for various diseases and syndromes in
TCM practice. Therefore, each TCM doctor can diagnose sub-
jectively with disease and syndromes. Consequently, poorly
repeatable diagnoses can be made. Such a lack of standard
methodology may produce a ‘trial and error’ therapy in prac-
tice. In this situation, one can hardly expect a standard guide-
line for TCM therapy. In order to work out these problems, the
NPRI Center proposed that the Regional Office should for-
mally invite an expert working group meeting and discuss
issues on examining the feasibility of establishing a standard
guideline for TCM therapy. Immediate action was taken by the
Regional Office, and the expert meeting with the title of ‘The
Informal Consultation on the Development of Treatment
Guidelines on Evidence-based Traditional Medicine’ organ-
ized by the Regional Office and the NPRI Center was held in
Seoul on May 27–29, 2004. Experts from TCM and comple-
mentary and alternative medicine (CAM), regulatory agencies,
conventional medical (Western medicine) and traditional med-
ical educational institutes, governmental policy makers from
China, Korea, Japan, Taiwan, the USA and a special group of
editorial staff members from eCAM gathered and produced the
following outcome, summarized as follows.
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Diseases of High Priority
To develop treatment guidelines for evidence-based TM, par-
ticipants from China, Japan and Korea submitted lists of target
diseases based on their own TM development strategies. Since
all countries were not represented, a list of diseases was sub-
mitted by the Regional Office to include the whole western
Pacific region.
China
● Hemorrhagic stroke
● Ischemic stroke
● Cardiovascular disease
● Coronary disease
● Acute myocardial infarction
● Acute coronary syndrome
● Hypertension
● Metabolic syndromes (hypertension, hyperlipidemia,
diabetes, obesity, etc.)
● Hepatitis (especially hepatitis B)
● Cancer (lung, liver, prostate, bladder)
● Influenza
● Pain syndromes (including headache, migraine, shoulder
pain, back pain, etc.)
● Facial paralysis
● Pediatric diseases (infant diarrhea)
● Respiratory diseases (pneumonia)
● Parkinson’s disease
● Pediatric diseases (nocturia, atopic dermatitis, epilepsy)
● Dementia
● AIDS
● Drug dependence
● Digestive diseases
● Osteoporosis
Japan
● Allergies
● Hypertension
● Coronary disease
● Cancer
● Metabolic diseases (including diabetes)
● Senile diseases (dementia)
● Pediatric diseases (atopic dermatitis)
● Psychological depression
Korea
● Hepatitis (B, C)
● Cardiovascular disease (including myocardial infarction,
coronary disease, hypertension, hypotension)
● Gastrointestinal disease (including gastritis, peptic ulcer,
Crohn’s disease, irritable bowel syndrome)
● Respiratory diseases (chronic asthma, bronchitis)
● Influenza
● Metabolic (diabetes, thyroid diseases, obesity, hypercho-
lesterol, high uric acid, osteoporosis)
● Musculoskeletal diseases (HIVD, ankylosing spondylitis,
arthritis)
● Brain and neurological disorders (stroke, Parkinson’s dis-
ease, multiple sclerosis)
● Peripheral neuropathy, facial paralysis, myasthenia
gravis, muscular dystrophy, ALS
● EENT disorders (glaucoma, tinnitus, rhinitis, cataract)
● Skin diseases
● Gynecological diseases (dysmenorrhea, post-menopausal
syndrome).
● Pediatric diseases (nocturia, atopic dermatitis, epilepsy,
infant diarrhea)
● Neuropsychiatric syndrome (depression, dementia,
neurosis)
● Cancer
● Allergy
● Pain syndromes (including headache, migraine, shoulder
pain, back pain, etc.)
● AIDS
● Drug dependence
The whole Pacific Region submitted by 
the Regional Office
● Hepatitis (B)
● Cardiovascular disease (including myocardial infarction,
coronary disease, hypertension)
● Gastrointestinal disease (including gastritis, peptic 
ulcer)
● Respiratory diseases (chronic asthma, bronchitis)
● Influenza
● Metabolic (diabetes, thyroid diseases, obesity, hypercho-
lesterol, high uric acid, osteoporosis)
● Musculoskeletal diseases (HIVD, ankylosing spondylitis,
arthritis)
● Brain and neurological disorders (stroke, Parkinson’s
disease, multiple sclerosis)
● Peripheral neuropathy, facial paralysis, myasthenia
gravis, muscular dystrophy, ALS
● EENT disorders (glaucoma, tinnitus, rhinitis, cataract)
● Skin diseases
● Gynecological diseases (dysmenorrhea, post-menopausal
syndrome)
● Pediatric diseases (nocturia, atopic dermatitis, epilepsy,
infant diarrhea)
● Neuropsychiatric syndrome (depression, dementia,
neurosis)
● Cancer
● Allergy
● Pain syndromes (including headache, migraine, shoulder
pain, back pain, etc.)
● AIDS
● Drug dependenceeCAM 2004;1(3) 339
The Process of Developing Treatment
Guidelines for Evidence-Based 
Traditional Medicine
Purpose
I. To pursue evidence-based scientific assessment
A. The content of evidence
B. The quality of evidence
II. Standardization of clinical practice
A. For achievement of reliability
B. For achievement of reproducibility
The Process
I. Selection of Guideline topics
A. Specific diseases
(i) In terms of traditional classification
(ii) In terms of modern classification
B. Rationale for using traditional medicine
(i) Limited availability and efficacy of modern
(Western, orthodox) therapy
(ii) Socioeconomic factors (high cost of modern
therapies)
(iii) Urgency and benefits of evaluating new treat-
ments derived from traditional medical therapy
Based on the above recommendation, the Regional Office
took prompt action as the first step to organize an expert
working group meeting in Beijing in October, 2004, on com-
mon TCM terminology that is essential for developing the
Guidelines.
CAM has evolved as a part of conventional medicine over
the past decade. TCM is playing an important role in CAM,
and it is an urgent task to develop a global standard of TCM
practice and herbal medicines as well as for mutual recogni-
tion and understanding. To achieve the goal, efforts have been
made to push forward with the standardization of TCM by
international collaboration through the WHO’s activities.
II. Formation of an Expert Team (Committee) by WHO
Western Pacific Regional Office
A. Regional base
(i) China, Japan, and Korea
(ii) Other Member States
B. Formation
(i) Expert clinicians, basic scientists (pharmacolo-
gists, toxicologists, epidemiologists, and others,
if needed), information scientists for literature
review, and experts from regulatory agencies
and non-governmental organizations
(ii) Formation of subcommittees for specific
purposes
C. Function
(i) Develop key clinical questions
(ii) Review literature: traditional medical classics,
modern scientific reports and relevant databases
(iii) Draft the Guidelines
III. Peer review
A. Extensive review of the drafted Guidelines
(i) Clinical specialists
(ii) Regional associations and clinicians’organizations
(iii) Regulatory agencies
B. Points of review
(i) Accuracy and quality
(ii) Thoroughness of drafted Guidelines
IV. Approval by the WHO Western Pacific Regional Office
A. Publication of the monographs
B. Recommendation
(i) Dissemination
(ii) Implementation of guidelines
(iii) Periodic revision of guidelines
Processing the Guidelines
I. Key clinical questions should comprise the following
components:
A. TM diagnosis for specific illness (modern diagnosis is
desirable)
B. Planning of therapy based on diagnosis; expected
rationale and end-points of efficacy before treatment
(acupuncture, moxibustion and herbal formulae)
C. Variation of treatments; rationale and end-points of
efficacy changed during therapy
D. Final outcomes should include the following:
(i) Statistical analysis indicating definite efficacy
(ii) Modern assay methods that measure end-points
during therapy
(iii) Benefits compared with modern therapy
II. Review of the literature
A. Searching traditional medical classics for the origin
of the therapy
(i) Bibliographic studies (Chinese, Japanese,
Korean and others)
(ii) Searching of relevant databases (TradiMed,
TCMLAS and others)
B. Modern literature related to the diseases
(i) Bibliographic studies on various therapies
(ii) Searching databases (Medline, Napralert, STN,
Agricola, Cochrane, and others)
(iii) Information on herbal formulae as pharmaceuti-
cal preparations registered to regional regulatory
agencies
C. Review of abstracts and full texts
(i) Review of abstracts; determination of total
number and significance of publications
(ii) Selection of information (classic and modern arti-
cles) for detailed study based on quality of literature
(iii) Review of full texts; determination of total number
and significance of publications. Quality of texts
will be evaluated using the following parameters:
(a) Well-controlled clinical trials applying
Good Clinical Practice (GCP).
(b) Clinical papers based on case reports.340 Meeting Report
(c) Availability of non-clinical data (Good Laboratory
Practice) with respect to the efficacy and the safety
of herbal formulae
(d) Acupuncture and moxibustion practiced in accor-
dance with standardized methods
D. Assessment of the literature review: does it support
the development of Guidelines?
(i) Yes
(ii) No (more data needed)
III. Finalize the Guidelines
A. A task-force team/subcommittee will be formed
(i) Data will be collected and evaluated
(ii) Data will be formulated into a Guideline with
specific recommendations that ensure efficacy
and safety of treatments.
B. The Guidelines will include:
(i) A title
(ii) An introduction that outlines the objectives of
key clinical questions
(iii) Bibliographic sources
(iv) A summary of evidence relevant to the key
clinical questions
(v) Recommendations for practice
(vi) WHO disclaimer
(vii) Identification of possible gaps in the current
Guidelines and directions for future research.
Recommendations
1. WHO should promote the proper use of Traditional
Medicine according to the Guidelines.
2. Member states should assist with clinical trials to
develop treatment guidelines.
3. The development of the Guidelines should be multidisci-
plinary, multinational and multicentered.
4. The WHO should harmonize the differences in prepara-
tion methods of traditional drugs in the different Member
States.
5. WHO should conduct training sessions on the principles
of evidence-based traditional medicine.
6. The WHO should support the preparation of the
Guidelines to promote the integration of traditional med-
icine with modern medicine for the benefit of mankind.
Fee copies of ‘The Draft Report on the Development of
Treatment Guideline on Evidence-based Traditional Medicine’
are available on request.
FHH Standing Committee and Conference
September 20-21, Shanghai, China
Figure 1. FHH’s standing committee and conference meeting.eCAM 2004;1(3) 341
W.H.O. Working Group Meeting on Development of
Treatment Guideline on Evidence-based Traditional Medicine
May 27-28, Seoul, Korea
Figure 2. WHO Informal Consultation Meeting on Development of Treatment Guideline on Traditional Medicine.